397 related articles for article (PubMed ID: 20185007)
21. Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Zhao L; Wang L; Zhang Y
J Invasive Cardiol; 2009 Oct; 21(10):493-8. PubMed ID: 19805833
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention.
McCullough P
Catheter Cardiovasc Interv; 2006 Mar; 67(3):335-43. PubMed ID: 16489569
[TBL] [Abstract][Full Text] [Related]
23. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality.
Roghi A; Savonitto S; Cavallini C; Arraiz G; Angoli L; Castriota F; Bernardi G; Sansa M; De Servi S; Pitscheider W; Danzi GB; Reimers B; Klugmann S; Zaninotto M; Ardissino D;
J Cardiovasc Med (Hagerstown); 2008 Apr; 9(4):375-81. PubMed ID: 18334892
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Patti G; Nusca A; Chello M; Pasceri V; D'Ambrosio A; Vetrovec GW; Di Sciascio G
Am J Cardiol; 2008 Feb; 101(3):279-85. PubMed ID: 18237585
[TBL] [Abstract][Full Text] [Related]
25. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease.
Toprak O; Cirit M; Esi E; Postaci N; Yesil M; Bayata S
Catheter Cardiovasc Interv; 2006 Feb; 67(2):227-35. PubMed ID: 16400673
[TBL] [Abstract][Full Text] [Related]
26. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
Spargias K; Alexopoulos E; Kyrzopoulos S; Iokovis P; Greenwood DC; Manginas A; Voudris V; Pavlides G; Buller CE; Kremastinos D; Cokkinos DV
Circulation; 2004 Nov; 110(18):2837-42. PubMed ID: 15492300
[TBL] [Abstract][Full Text] [Related]
27. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study.
Recio-Mayoral A; Chaparro M; Prado B; Cózar R; Méndez I; Banerjee D; Kaski JC; Cubero J; Cruz JM
J Am Coll Cardiol; 2007 Mar; 49(12):1283-8. PubMed ID: 17394959
[TBL] [Abstract][Full Text] [Related]
28. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions.
Khanal S; Attallah N; Smith DE; Kline-Rogers E; Share D; O'Donnell MJ; Moscucci M
Am J Med; 2005 Aug; 118(8):843-9. PubMed ID: 16084176
[TBL] [Abstract][Full Text] [Related]
29. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
[TBL] [Abstract][Full Text] [Related]
30. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention.
Nyman U; Björk J; Aspelin P; Marenzi G
Acta Radiol; 2008 Jul; 49(6):658-67. PubMed ID: 18568558
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
[TBL] [Abstract][Full Text] [Related]
32. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
33. Protection of radiocontrast induced nephropathy by vitamin E (alpha tocopherol): a randomized controlled pilot study.
Tasanarong A; Piyayotai D; Thitiarchakul S
J Med Assoc Thai; 2009 Oct; 92(10):1273-81. PubMed ID: 19845233
[TBL] [Abstract][Full Text] [Related]
34. Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention.
Conen D; Buerkle G; Perruchoud AP; Buettner HJ; Mueller C
Int J Cardiol; 2006 Jun; 110(2):237-41. PubMed ID: 16298441
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
[TBL] [Abstract][Full Text] [Related]
36. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.
Bartholomew BA; Harjai KJ; Dukkipati S; Boura JA; Yerkey MW; Glazier S; Grines CL; O'Neill WW
Am J Cardiol; 2004 Jun; 93(12):1515-9. PubMed ID: 15194023
[TBL] [Abstract][Full Text] [Related]
37. Contrast-induced nephropathy and risk of acute kidney injury and mortality after cardiac operations.
Garcia S; Ko B; Adabag S
Ann Thorac Surg; 2012 Sep; 94(3):772-6. PubMed ID: 22835553
[TBL] [Abstract][Full Text] [Related]
38. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure.
Masuda M; Yamada T; Mine T; Morita T; Tamaki S; Tsukamoto Y; Okuda K; Iwasaki Y; Hori M; Fukunami M
Am J Cardiol; 2007 Sep; 100(5):781-6. PubMed ID: 17719320
[TBL] [Abstract][Full Text] [Related]
39. Incidence of contrast-induced nephropathy with volume supplementation--insights from a large cohort.
Mueller-Lenke N; Buerkle G; Klima T; Breidthardt T; Buettner HJ; Mueller C
Med Princ Pract; 2008; 17(5):409-14. PubMed ID: 18685283
[TBL] [Abstract][Full Text] [Related]
40. The incidence of contrast-induced nephropathy in trauma patients.
Hipp A; Desai S; Lopez C; Sinert R
Eur J Emerg Med; 2008 Jun; 15(3):134-9. PubMed ID: 18460952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
